Icon (ICLR) Stock Forecast & Price Target

$185.06 -3.40 (-1.80%)

Closing price 10/17/2025 04:00 PM Eastern

Extended Trading

$185.48 +0.42 (+0.23%)

As of 10/17/2025 05:27 PM Eastern

Compare

Icon - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
8

Buy
11

Based on 19 Wall Street analysts who have issued ratings for Icon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 8 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for ICLR.

Consensus Price Target

$210.64
13.82% Upside

According to the 19 analysts' twelve-month price targets for Icon, the average price target is $210.64. The highest price target for ICLR is $263.00, while the lowest price target for ICLR is $150.00. The average price target represents a forecasted upside of 13.82% from the current price of $185.06.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Icon and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ICLR Analyst Ratings Over Time

Type	Current Forecast 10/18/24 to 10/18/25	1 Month Ago 9/18/24 to 9/18/25	3 Months Ago 7/20/24 to 7/20/25	1 Year Ago 10/19/23 to 10/18/24
Strong Buy	2 Strong Buy rating(s)	3 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)	11 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$210.64	$216.67	$198.08	$346.09
Forecasted Upside	13.82% Upside	20.75% Upside	38.00% Upside	16.25% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Icon Stock vs. The Competition

Type	Icon	Medical Companies	S&P 500
Consensus Rating Score	2.68	2.33	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	13.82% Upside	1,356.34% Upside	13.60% Upside
News Sentiment Rating	Positive News See Recent ICLR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/8/2025	Weiss Ratings 0 of 5 stars		Reiterated Rating	Hold (C)
10/2/2025	Barclays 3 of 5 stars	Luke Sergott Not Rated	Boost Target	Equal Weight	$180.00 ➝ $190.00	-1.20%
9/12/2025	Cowen 1 of 5 stars		Reiterated Rating	Hold
9/9/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$220.00 ➝ $175.00	-1.58%
9/3/2025	Rothschild Redb Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
9/3/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$184.00 ➝ $236.00	+32.70%
9/2/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Coldwell Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$222.00 ➝ $224.00	+27.11%
8/21/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Donnelly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$225.00 ➝ $200.00	+10.96%
7/25/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$173.00 ➝ $225.00	+22.29%
7/25/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jailendra Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$187.00 ➝ $234.00	+26.14%
Get the Latest News and Ratings for ICLR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Icon and its competitors with MarketBeat's FREE daily newsletter.
7/25/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Sourbeer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$170.00 ➝ $240.00	+29.32%
7/25/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ross Muken Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$170.00 ➝ $240.00	+28.37%
7/24/2025	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
5/2/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Sykes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$180.00 ➝ $160.00	+9.30%
4/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Casey Woodring Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$265.00 ➝ $150.00	+3.45%
4/14/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$254.00 ➝ $157.00	+9.00%
1/15/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Dodge Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$263.00 ➝ $263.00	+29.67%
1/14/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform
11/19/2024	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$270.00 ➝ $255.00	+34.38%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Neutral	$311.00	+5.43%
9/18/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:31 AM ET.

Should I Buy Icon Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 14, 2025. Please send any questions or comments about these Icon pros and cons to contact@marketbeat.com.

Icon
Bull Case

Here are some ways that investors could benefit from investing in ICON Public Limited:

The current stock price is around $183, which may present a buying opportunity for investors looking for growth in the clinical research sector.
ICON Public Limited reported earnings per share (EPS) of $3.26 for the latest quarter, exceeding analyst expectations, indicating strong financial performance.
The company has a solid market capitalization of approximately $14.35 billion, reflecting its stability and presence in the market.
With a return on equity of 10.95%, ICON Public Limited demonstrates effective management and profitability, which can attract investors seeking reliable returns.
Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price suggesting potential upside, indicating positive market sentiment.

Icon
Bear Case

Investors should be bearish about investing in ICON Public Limited for these reasons:

The company's revenue for the latest quarter was down about 4.8% compared to the same period last year, which may raise concerns about growth sustainability.
ICON Public Limited has a price-to-earnings (P/E) ratio of 18.27, which could be considered high, suggesting that the stock may be overvalued relative to its earnings.
With a PEG ratio of 2.57, the stock may not be as attractive for growth investors, as this indicates that the stock price is high relative to its expected growth rate.
The stock has experienced significant volatility, with a beta of 1.20, meaning it is more volatile than the market, which could pose risks for conservative investors.
Recent downgrades from analysts, including a reduction in price targets, may signal caution and uncertainty about the company's future performance.

ICLR Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Icon is $210.64, with a high forecast of $263.00 and a low forecast of $150.00.
: 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icon in the last twelve months. There are currently 8 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ICLR shares.
: According to analysts, Icon's stock has a predicted upside of 13.82% based on their 12-month stock forecasts.
: Over the previous 90 days, Icon's stock had 4 upgrades and 1 downgrade by analysts.
: Icon has been rated by research analysts at Baird R W, Barclays, Citigroup, Cowen, Evercore ISI, Jefferies Financial Group, Mizuho, Robert W. Baird, Rothschild & Co Redburn, Rothschild Redb, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.
: Analysts like Icon more than other "medical" companies. The consensus rating for Icon is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ICLR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ICLR) was last updated on 10/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Icon (ICLR) Stock Forecast & Price Target